Skip to main content
Top
Published in: Arthritis Research & Therapy 1/2012

Open Access 01-02-2012 | Research article

Hyperuricemia and untreated gout are poor prognostic markers among those with a recent acute myocardial infarction

Authors: Eswar Krishnan, Bhavik J Pandya, Bharathi Lingala, Ali Hariri, Omar Dabbous

Published in: Arthritis Research & Therapy | Issue 1/2012

Login to get access

Abstract

Introduction

Patients with a history of myocardial infarction (MI) are often at risk for complications, including subsequent MI and death. Use of prognostic markers may aid in preventing these poor outcomes. Hyperuricemia is associated with increased risk for coronary heart disease (CHD) and/or mortality; however, it is unknown if serum urate (sUA) levels predict outcomes in patients with previous MI. The purpose of this study was to assess hyperuricemia as a biomarker of CHD outcomes in such patients.

Methods

These were post hoc analyses of datasets from the Aspirin Myocardial Infarction Study, a 1:1 randomized, double-blind clinical trial, conducted from 1975 to 1979, that examined mortality rates following daily aspirin administration over three years in individuals with documented MI. The primary outcome measures were all-cause death, CHD mortality, coronary incidence, and stroke by quartile of baseline sUA. A sub-analysis of all outcome measures in the presence or absence of gouty arthritis was also performed.

Results

Of 4,524 enrolled participants, data on 4,352 were analyzed here. All outcomes were greatest for patients in the fourth sUA quartile. In multivariate regression models, the hazard ratios (HR) for patients in the highest quartile were 1.88 for all-cause mortality (95% confidence interval (CI), 1.45 to 2.46), 1.99 for CHD mortality (95% CI, 1.49 to 2.66), and 1.36 for coronary incidence (95% CI, 1.08 to 1.70). Participants with untreated gout had an adjusted hazard ratio ranging from 1.5 to 2.0 (all P < 0.01) for these outcomes. Participants with gout who were receiving treatment did not exhibit this additional risk.

Conclusions

sUA and untreated gout may be independent prognostic markers for poor all-cause and CHD mortality in patients with recent acute MI.
Appendix
Available only for authorised users
Literature
1.
go back to reference Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De Simone G, Ferguson TB, Ford E, Furie K, Gillespie C, Go A, Greenlund K, Haase N, Hailpern S, Ho PM, Howard V, Kissela B, Kittner S, Lackland D, Lisabeth L, Marelli A, McDermott MM, Meigs J, Mozaffarian D, Mussolino M, Nichol G, Roger VL, Rosamond W, Sacco R, Sorlie P, et al: Executive summary: heart disease and stroke statistics--2010 update: a report from the American Heart Association. Circulation. 2010, 121: 948-954.CrossRefPubMed Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De Simone G, Ferguson TB, Ford E, Furie K, Gillespie C, Go A, Greenlund K, Haase N, Hailpern S, Ho PM, Howard V, Kissela B, Kittner S, Lackland D, Lisabeth L, Marelli A, McDermott MM, Meigs J, Mozaffarian D, Mussolino M, Nichol G, Roger VL, Rosamond W, Sacco R, Sorlie P, et al: Executive summary: heart disease and stroke statistics--2010 update: a report from the American Heart Association. Circulation. 2010, 121: 948-954.CrossRefPubMed
2.
go back to reference Cannon CP, Greenberg BH: Risk stratification and prognostic factors in the post-myocardial infarction patient. Am J Cardiol. 2008, 102: 13G-20G. 10.1016/j.amjcard.2008.06.006.CrossRefPubMed Cannon CP, Greenberg BH: Risk stratification and prognostic factors in the post-myocardial infarction patient. Am J Cardiol. 2008, 102: 13G-20G. 10.1016/j.amjcard.2008.06.006.CrossRefPubMed
3.
go back to reference Morrow DA, Cannon CP, Rifai N, Frey MJ, Vicari R, Lakkis N, Robertson DH, Hille DA, DeLucca PT, DiBattiste PM, Demopoulos LA, Weintraub WS, Braunwald E: Ability of minor elevations of troponins I and T to predict benefit from an early invasive strategy in patients with unstable angina and non-ST elevation myocardial infarction: results from a randomized trial. JAMA. 2001, 286: 2405-2412. 10.1001/jama.286.19.2405.CrossRefPubMed Morrow DA, Cannon CP, Rifai N, Frey MJ, Vicari R, Lakkis N, Robertson DH, Hille DA, DeLucca PT, DiBattiste PM, Demopoulos LA, Weintraub WS, Braunwald E: Ability of minor elevations of troponins I and T to predict benefit from an early invasive strategy in patients with unstable angina and non-ST elevation myocardial infarction: results from a randomized trial. JAMA. 2001, 286: 2405-2412. 10.1001/jama.286.19.2405.CrossRefPubMed
4.
go back to reference Kavsak PA, Ko DT, Newman AM, Palomaki GE, Lustig V, MacRae AR, Jaffe AS: Risk stratification for heart failure and death in an acute coronary syndrome population using inflammatory cytokines and N-terminal pro-brain natriuretic peptide. Clin Chem. 2007, 53: 2112-2118. 10.1373/clinchem.2007.090613.CrossRefPubMed Kavsak PA, Ko DT, Newman AM, Palomaki GE, Lustig V, MacRae AR, Jaffe AS: Risk stratification for heart failure and death in an acute coronary syndrome population using inflammatory cytokines and N-terminal pro-brain natriuretic peptide. Clin Chem. 2007, 53: 2112-2118. 10.1373/clinchem.2007.090613.CrossRefPubMed
5.
go back to reference Kavsak PA, MacRae AR, Newman AM, Lustig V, Palomaki GE, Ko DT, Tu JV, Jaffe AS: Elevated C-reactive protein in acute coronary syndrome presentation is an independent predictor of long-term mortality and heart failure. Clin Biochem. 2007, 40: 326-329. 10.1016/j.clinbiochem.2006.10.025.CrossRefPubMed Kavsak PA, MacRae AR, Newman AM, Lustig V, Palomaki GE, Ko DT, Tu JV, Jaffe AS: Elevated C-reactive protein in acute coronary syndrome presentation is an independent predictor of long-term mortality and heart failure. Clin Biochem. 2007, 40: 326-329. 10.1016/j.clinbiochem.2006.10.025.CrossRefPubMed
6.
go back to reference Krishnan E, Pandya BJ, Chung L, Dabbous O: Hyperuricemia and the risk for subclinical coronary atherosclerosis-data from a prospective observational cohort study. Arthritis Res Ther. 2011, 13: R66-10.1186/ar3322.PubMedCentralCrossRefPubMed Krishnan E, Pandya BJ, Chung L, Dabbous O: Hyperuricemia and the risk for subclinical coronary atherosclerosis-data from a prospective observational cohort study. Arthritis Res Ther. 2011, 13: R66-10.1186/ar3322.PubMedCentralCrossRefPubMed
7.
go back to reference Baker JF, Krishnan E, Chen L, Schumacher HR: Serum uric acid and cardiovascular disease: recent developments, and where do they leave us?. Am J Med. 2005, 118: 816-826. 10.1016/j.amjmed.2005.03.043.CrossRefPubMed Baker JF, Krishnan E, Chen L, Schumacher HR: Serum uric acid and cardiovascular disease: recent developments, and where do they leave us?. Am J Med. 2005, 118: 816-826. 10.1016/j.amjmed.2005.03.043.CrossRefPubMed
8.
go back to reference Krishnan E: Gout and coronary artery disease: epidemiologic clues. Curr Rheumatol Rep. 2008, 10: 249-255. 10.1007/s11926-008-0039-0.CrossRefPubMed Krishnan E: Gout and coronary artery disease: epidemiologic clues. Curr Rheumatol Rep. 2008, 10: 249-255. 10.1007/s11926-008-0039-0.CrossRefPubMed
9.
go back to reference A randomized, controlled trial of aspirin in persons recovered from myocardial infarction. JAMA. 1980, 243: 661-669. A randomized, controlled trial of aspirin in persons recovered from myocardial infarction. JAMA. 1980, 243: 661-669.
10.
go back to reference Choi HK, Atkinson K, Karlson EW, Willett W, Curhan G: Purine-rich foods, dairy and protein intake, and the risk of gout in men. N Engl J Med. 2004, 350: 1093-1103. 10.1056/NEJMoa035700.CrossRefPubMed Choi HK, Atkinson K, Karlson EW, Willett W, Curhan G: Purine-rich foods, dairy and protein intake, and the risk of gout in men. N Engl J Med. 2004, 350: 1093-1103. 10.1056/NEJMoa035700.CrossRefPubMed
11.
go back to reference Gelber AC, Klag MJ, Mead LA, Thomas J, Thomas DJ, Pearson TA, Hochberg MC: Gout and risk for subsequent coronary heart disease. The Meharry-Hopkins Study. Arch Intern Med. 1997, 157: 1436-1440. 10.1001/archinte.1997.00440340060005.CrossRefPubMed Gelber AC, Klag MJ, Mead LA, Thomas J, Thomas DJ, Pearson TA, Hochberg MC: Gout and risk for subsequent coronary heart disease. The Meharry-Hopkins Study. Arch Intern Med. 1997, 157: 1436-1440. 10.1001/archinte.1997.00440340060005.CrossRefPubMed
12.
go back to reference McAdams MA, Maynard JW, Baer AN, Kottgen A, Clipp S, Coresh J, Gelber AC: Reliability and sensitivity of the self-report of physician-diagnosed gout in the campaign against cancer and heart disease and the atherosclerosis risk in the community cohorts. J Rheumatol. 2011, 38: 135-141. 10.3899/jrheum.100418.PubMedCentralCrossRefPubMed McAdams MA, Maynard JW, Baer AN, Kottgen A, Clipp S, Coresh J, Gelber AC: Reliability and sensitivity of the self-report of physician-diagnosed gout in the campaign against cancer and heart disease and the atherosclerosis risk in the community cohorts. J Rheumatol. 2011, 38: 135-141. 10.3899/jrheum.100418.PubMedCentralCrossRefPubMed
13.
go back to reference Dalbeth N, Kumar S, Stamp L, Gow P: Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout. J Rheumatol. 2006, 33: 1646-1650.PubMed Dalbeth N, Kumar S, Stamp L, Gow P: Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout. J Rheumatol. 2006, 33: 1646-1650.PubMed
14.
go back to reference Sarawate CA, Brewer KK, Yang W, Patel PA, Schumacher HR, Saag KG, Bakst AW: Gout medication treatment patterns and adherence to standards of care from a managed care perspective. Mayo Clin Proc. 2006, 81: 925-934. 10.4065/81.7.925.CrossRefPubMed Sarawate CA, Brewer KK, Yang W, Patel PA, Schumacher HR, Saag KG, Bakst AW: Gout medication treatment patterns and adherence to standards of care from a managed care perspective. Mayo Clin Proc. 2006, 81: 925-934. 10.4065/81.7.925.CrossRefPubMed
15.
go back to reference Brodov Y, Chouraqui P, Goldenberg I, Boyko V, Mandelzweig L, Behar S: Serum uric acid for risk stratification of patients with coronary artery disease. Cardiology. 2009, 114: 300-305. 10.1159/000239860.CrossRefPubMed Brodov Y, Chouraqui P, Goldenberg I, Boyko V, Mandelzweig L, Behar S: Serum uric acid for risk stratification of patients with coronary artery disease. Cardiology. 2009, 114: 300-305. 10.1159/000239860.CrossRefPubMed
16.
go back to reference Ioachimescu AG, Brennan DM, Hoar BM, Hazen SL, Hoogwerf BJ: Serum uric acid is an independent predictor of all-cause mortality in patients at high risk of cardiovascular disease: a preventive cardiology information system (PreCIS) database cohort study. Arthritis Rheum. 2008, 58: 623-630. 10.1002/art.23121.CrossRefPubMed Ioachimescu AG, Brennan DM, Hoar BM, Hazen SL, Hoogwerf BJ: Serum uric acid is an independent predictor of all-cause mortality in patients at high risk of cardiovascular disease: a preventive cardiology information system (PreCIS) database cohort study. Arthritis Rheum. 2008, 58: 623-630. 10.1002/art.23121.CrossRefPubMed
17.
go back to reference Thanassoulis G, Brophy JM, Richard H, Pilote L: Gout, allopurinol use, and heart failure outcomes. Arch Intern Med. 2010, 170: 1358-1364. 10.1001/archinternmed.2010.198.CrossRefPubMed Thanassoulis G, Brophy JM, Richard H, Pilote L: Gout, allopurinol use, and heart failure outcomes. Arch Intern Med. 2010, 170: 1358-1364. 10.1001/archinternmed.2010.198.CrossRefPubMed
18.
go back to reference Kim SY, Guevara JP, Kim KM, Choi HK, Heitjan DF, Albert DA: Hyperuricemia and risk of stroke: a systematic review and meta-analysis. Arthritis Rheum. 2009, 61: 885-892. 10.1002/art.24612.PubMedCentralCrossRefPubMed Kim SY, Guevara JP, Kim KM, Choi HK, Heitjan DF, Albert DA: Hyperuricemia and risk of stroke: a systematic review and meta-analysis. Arthritis Rheum. 2009, 61: 885-892. 10.1002/art.24612.PubMedCentralCrossRefPubMed
19.
go back to reference Chen JH, Chuang SY, Chen HJ, Yeh WT, Pan WH: Serum uric acid level as an independent risk factor for all-cause, cardiovascular, and ischemic stroke mortality: a Chinese cohort study. Arthritis Rheum. 2009, 61: 225-232. 10.1002/art.24164.CrossRefPubMed Chen JH, Chuang SY, Chen HJ, Yeh WT, Pan WH: Serum uric acid level as an independent risk factor for all-cause, cardiovascular, and ischemic stroke mortality: a Chinese cohort study. Arthritis Rheum. 2009, 61: 225-232. 10.1002/art.24164.CrossRefPubMed
20.
go back to reference The aspirin myocardial infarction study: final results. The Aspirin Myocardial Infarction Study research group. Circulation. 1980, 62: V79-84. The aspirin myocardial infarction study: final results. The Aspirin Myocardial Infarction Study research group. Circulation. 1980, 62: V79-84.
21.
go back to reference Caspi D, Lubart E, Graff E, Habot B, Yaron M, Segal R: The effect of mini-dose aspirin on renal function and uric acid handling in elderly patients. Arthritis Rheum. 2000, 43: 103-108. 10.1002/1529-0131(200001)43:1<103::AID-ANR13>3.0.CO;2-C.CrossRefPubMed Caspi D, Lubart E, Graff E, Habot B, Yaron M, Segal R: The effect of mini-dose aspirin on renal function and uric acid handling in elderly patients. Arthritis Rheum. 2000, 43: 103-108. 10.1002/1529-0131(200001)43:1<103::AID-ANR13>3.0.CO;2-C.CrossRefPubMed
22.
23.
go back to reference Krishnan E: Inflammation, oxidative stress and lipids: the risk triad for atherosclerosis in gout. Rheumatology (Oxford). 2010, 49: 1229-1238. 10.1093/rheumatology/keq037.CrossRef Krishnan E: Inflammation, oxidative stress and lipids: the risk triad for atherosclerosis in gout. Rheumatology (Oxford). 2010, 49: 1229-1238. 10.1093/rheumatology/keq037.CrossRef
24.
go back to reference Kanellis J, Watanabe S, Li JH, Kang DH, Li P, Nakagawa T, Wamsley A, Sheikh-Hamad D, Lan HY, Feng L, Johnson RJ: Uric acid stimulates monocyte chemoattractant protein-1 production in vascular smooth muscle cells via mitogen-activated protein kinase and cyclooxygenase-2. Hypertension. 2003, 41: 1287-1293. 10.1161/01.HYP.0000072820.07472.3B.CrossRefPubMed Kanellis J, Watanabe S, Li JH, Kang DH, Li P, Nakagawa T, Wamsley A, Sheikh-Hamad D, Lan HY, Feng L, Johnson RJ: Uric acid stimulates monocyte chemoattractant protein-1 production in vascular smooth muscle cells via mitogen-activated protein kinase and cyclooxygenase-2. Hypertension. 2003, 41: 1287-1293. 10.1161/01.HYP.0000072820.07472.3B.CrossRefPubMed
25.
go back to reference Gersch C, Palii SP, Imaram W, Kim KM, Karumanchi SA, Angerhofer A, Johnson RJ, Henderson GN: Reactions of peroxynitrite with uric acid: formation of reactive intermediates, alkylated products and triuret, and in vivo production of triuret under conditions of oxidative stress. Nucleosides Nucleotides Nucleic Acids. 2009, 28: 118-149. 10.1080/15257770902736400.PubMedCentralCrossRefPubMed Gersch C, Palii SP, Imaram W, Kim KM, Karumanchi SA, Angerhofer A, Johnson RJ, Henderson GN: Reactions of peroxynitrite with uric acid: formation of reactive intermediates, alkylated products and triuret, and in vivo production of triuret under conditions of oxidative stress. Nucleosides Nucleotides Nucleic Acids. 2009, 28: 118-149. 10.1080/15257770902736400.PubMedCentralCrossRefPubMed
26.
go back to reference Corry DB, Eslami P, Yamamoto K, Nyby MD, Makino H, Tuck ML: Uric acid stimulates vascular smooth muscle cell proliferation and oxidative stress via the vascular renin-angiotensin system. J Hypertens. 2008, 26: 269-275. 10.1097/HJH.0b013e3282f240bf.CrossRefPubMed Corry DB, Eslami P, Yamamoto K, Nyby MD, Makino H, Tuck ML: Uric acid stimulates vascular smooth muscle cell proliferation and oxidative stress via the vascular renin-angiotensin system. J Hypertens. 2008, 26: 269-275. 10.1097/HJH.0b013e3282f240bf.CrossRefPubMed
27.
go back to reference Price KL, Sautin YY, Long DA, Zhang L, Miyazaki H, Mu W, Endou H, Johnson RJ: Human vascular smooth muscle cells express a urate transporter. J Am Soc Nephrol. 2006, 17: 1791-1795. 10.1681/ASN.2006030264.CrossRefPubMed Price KL, Sautin YY, Long DA, Zhang L, Miyazaki H, Mu W, Endou H, Johnson RJ: Human vascular smooth muscle cells express a urate transporter. J Am Soc Nephrol. 2006, 17: 1791-1795. 10.1681/ASN.2006030264.CrossRefPubMed
28.
go back to reference Mazzali M, Hughes J, Kim YG, Jefferson JA, Kang DH, Gordon KL, Lan HY, Kivlighn S, Johnson RJ: Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension. 2001, 38: 1101-1106. 10.1161/hy1101.092839.CrossRefPubMed Mazzali M, Hughes J, Kim YG, Jefferson JA, Kang DH, Gordon KL, Lan HY, Kivlighn S, Johnson RJ: Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension. 2001, 38: 1101-1106. 10.1161/hy1101.092839.CrossRefPubMed
29.
go back to reference George J, Carr E, Davies J, Belch JJ, Struthers A: High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid. Circulation. 2006, 114: 2508-2516. 10.1161/CIRCULATIONAHA.106.651117.CrossRefPubMed George J, Carr E, Davies J, Belch JJ, Struthers A: High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid. Circulation. 2006, 114: 2508-2516. 10.1161/CIRCULATIONAHA.106.651117.CrossRefPubMed
30.
go back to reference Mercuro G, Vitale C, Cerquetani E, Zoncu S, Deidda M, Fini M, Rosano GM: Effect of hyperuricemia upon endothelial function in patients at increased cardiovascular risk. Am J Cardiol. 2004, 94: 932-935. 10.1016/j.amjcard.2004.06.032.CrossRefPubMed Mercuro G, Vitale C, Cerquetani E, Zoncu S, Deidda M, Fini M, Rosano GM: Effect of hyperuricemia upon endothelial function in patients at increased cardiovascular risk. Am J Cardiol. 2004, 94: 932-935. 10.1016/j.amjcard.2004.06.032.CrossRefPubMed
31.
go back to reference Engberding N, Spiekermann S, Schaefer A, Heineke A, Wiencke A, Muller M, Fuchs M, Hilfiker-Kleiner D, Hornig B, Drexler H, Landmesser U: Allopurinol attenuates left ventricular remodeling and dysfunction after experimental myocardial infarction: a new action for an old drug?. Circulation. 2004, 110: 2175-2179. 10.1161/01.CIR.0000144303.24894.1C.CrossRefPubMed Engberding N, Spiekermann S, Schaefer A, Heineke A, Wiencke A, Muller M, Fuchs M, Hilfiker-Kleiner D, Hornig B, Drexler H, Landmesser U: Allopurinol attenuates left ventricular remodeling and dysfunction after experimental myocardial infarction: a new action for an old drug?. Circulation. 2004, 110: 2175-2179. 10.1161/01.CIR.0000144303.24894.1C.CrossRefPubMed
32.
go back to reference Guan W, Osanai T, Kamada T, Hanada H, Ishizaka H, Onodera H, Iwasa A, Fujita N, Kudo S, Ohkubo T, Okumura K: Effect of allopurinol pretreatment on free radical generation after primary coronary angioplasty for acute myocardial infarction. J Cardiovasc Pharmacol. 2003, 41: 699-705. 10.1097/00005344-200305000-00005.CrossRefPubMed Guan W, Osanai T, Kamada T, Hanada H, Ishizaka H, Onodera H, Iwasa A, Fujita N, Kudo S, Ohkubo T, Okumura K: Effect of allopurinol pretreatment on free radical generation after primary coronary angioplasty for acute myocardial infarction. J Cardiovasc Pharmacol. 2003, 41: 699-705. 10.1097/00005344-200305000-00005.CrossRefPubMed
33.
go back to reference Rentoukas E, Tsarouhas K, Tsitsimpikou C, Lazaros G, Deftereos S, Vavetsi S: The prognostic impact of allopurinol in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention. Int J Cardiol. 2010, 145: 257-258. 10.1016/j.ijcard.2009.08.037.CrossRefPubMed Rentoukas E, Tsarouhas K, Tsitsimpikou C, Lazaros G, Deftereos S, Vavetsi S: The prognostic impact of allopurinol in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention. Int J Cardiol. 2010, 145: 257-258. 10.1016/j.ijcard.2009.08.037.CrossRefPubMed
34.
go back to reference Tarkka MR, Vuolle M, Kaukinen S, Holm P, Eloranta J, Kaukinen U, Sisto T, Kataja J: Effect of allopurinol on myocardial oxygen free radical production in coronary bypass surgery. Scand Cardiovasc J. 2000, 34: 593-596. 10.1080/140174300750064549.CrossRefPubMed Tarkka MR, Vuolle M, Kaukinen S, Holm P, Eloranta J, Kaukinen U, Sisto T, Kataja J: Effect of allopurinol on myocardial oxygen free radical production in coronary bypass surgery. Scand Cardiovasc J. 2000, 34: 593-596. 10.1080/140174300750064549.CrossRefPubMed
35.
go back to reference Feig DI, Soletsky B, Johnson RJ: Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. JAMA. 2008, 300: 924-932. 10.1001/jama.300.8.924.PubMedCentralCrossRefPubMed Feig DI, Soletsky B, Johnson RJ: Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. JAMA. 2008, 300: 924-932. 10.1001/jama.300.8.924.PubMedCentralCrossRefPubMed
Metadata
Title
Hyperuricemia and untreated gout are poor prognostic markers among those with a recent acute myocardial infarction
Authors
Eswar Krishnan
Bhavik J Pandya
Bharathi Lingala
Ali Hariri
Omar Dabbous
Publication date
01-02-2012
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue 1/2012
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/ar3684

Other articles of this Issue 1/2012

Arthritis Research & Therapy 1/2012 Go to the issue